Literature DB >> 1608975

A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens.

X Fu1, F Guadagni, R M Hoffman.   

Abstract

Pancreatic cancer is one of the most intractable and least understood of all human cancers. Pancreatic cancers is the fourth-leading cause of cancer-related mortality in the United States with less than 2% of the patients surviving for 5 yr. In an effort to help develop more effective treatment modalities for pancreatic cancer and improve detection, we report an animal model for individual human pancreatic-cancer patients. The model involves orthotopic transplantation of histologically intact pancreatic-cancer specimens to the nude-mouse pancreas, which can result in models that resemble the clinical picture including (i) extensive local tumor growth, (ii) extension of the locally growing human pancreatic cancer to the nude-mouse stomach and duodenum, (iii) metastases of the human pancreatic tumor to the nude-mouse liver and regional lymph nodes, and (iv) distant metastases of the human pancreatic tumor to the nude-mouse adrenal gland, diaphragm, and mediastinal lymph nodes. In a series of five patient cases, a 100% take rate has been demonstrated, and of 17 mice transplanted, 15 supported tumor growth. Immunohistochemical analysis of the antigenic phenotype of the transplanted human pancreatic tumors showed a similar pattern of expression of two different human tumor-associated antigens, such as tumor-associated glycoprotein 72 and carcinoembryonic antigen in the transplanted tumors when compared with the original surgical biopsy, suggesting similarity between the two. This model should, therefore, prove valuable for treatment evaluation of individual cancer patients, as well as for evaluation of experimental treatment modalities for this disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1608975      PMCID: PMC49349          DOI: 10.1073/pnas.89.12.5645

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma.

Authors:  D Theodorescu; I Cornil; B J Fernandez; R S Kerbel
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

2.  Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture.

Authors:  I J Fidler
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 12.701

3.  Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice.

Authors:  J E Price; A Polyzos; R D Zhang; L M Daniels
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

4.  Comparison of the human tumor cloning and subrenal capsule assays.

Authors:  A E Bogden; D D Von Hoff
Journal:  Cancer Res       Date:  1984-03       Impact factor: 12.701

5.  Pancreatic cancer: an overview of epidemiology, clinical presentation, and diagnosis.

Authors:  J R Malagelada
Journal:  Mayo Clin Proc       Date:  1979-07       Impact factor: 7.616

6.  Site-selective growth of a hormone-responsive human breast carcinoma in athymic mice.

Authors:  A C White; J A Levy; C M McGrath
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

7.  A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice.

Authors:  J M Kozlowski; I R Hart; I J Fidler; N Hanna
Journal:  J Natl Cancer Inst       Date:  1984-04       Impact factor: 13.506

8.  Metastatic behavior of human tumor cell lines grown in the nude mouse.

Authors:  J M Kozlowski; I J Fidler; D Campbell; Z L Xu; M E Kaighn; I R Hart
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701

9.  Urothelial susceptibility to tumor cell implantation: comparison of cauterization with N-methyl-N-nitrosourea.

Authors:  M S Soloway; I Nissenkorn; L McCallum
Journal:  Urology       Date:  1983-02       Impact factor: 2.649

10.  Growth patterns and metastatic behavior of human tumors growing in athymic mice.

Authors:  A P Kyriazis; L DiPersio; G J Michael; A J Pesce; J D Stinnett
Journal:  Cancer Res       Date:  1978-10       Impact factor: 12.701

View more
  157 in total

1.  Metastatic models of human liver cancer in nude mice orthotopically constructed by using histologically intact patient specimens.

Authors:  F X Sun; Z Y Tang; K D Liu; Q Xue; D M Gao; Y Q Yu; X D Zhou; Z C Ma
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  Is tail vein injection a relevant breast cancer lung metastasis model?

Authors:  Omar M Rashid; Masayuki Nagahashi; Suburamaniam Ramachandran; Catherine I Dumur; Julia C Schaum; Akimitsu Yamada; Tomoyoshi Aoyagi; Sheldon Milstien; Sarah Spiegel; Kazuaki Takabe
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

3.  Knockdown of the β(1) integrin subunit reduces primary tumor growth and inhibits pancreatic cancer metastasis.

Authors:  John J Grzesiak; Hop S Tran Cao; Douglas W Burton; Sharmeela Kaushal; Fabian Vargas; Paul Clopton; Cynthia S Snyder; Leonard J Deftos; Robert M Hoffman; Michael Bouvet
Journal:  Int J Cancer       Date:  2011-04-13       Impact factor: 7.396

4.  Redirecting apoptosis to aponecrosis induces selective cytotoxicity to pancreatic cancer cells through increased ROS, decline in ATP levels, and VDAC.

Authors:  Richard D Dinnen; Yuehua Mao; Wanglong Qiu; Nicholas Cassai; Vesna N Slavkovich; Gwen Nichols; Gloria H Su; Paul Brandt-Rauf; Robert L Fine
Journal:  Mol Cancer Ther       Date:  2013-10-14       Impact factor: 6.261

5.  Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.

Authors:  Kei Kawaguchi; Kentaro Miyake; Qinghong Han; Shukuan Li; Yuying Tan; Kentaro Igarashi; Thinzar M Lwin; Takashi Higuchi; Tasuku Kiyuna; Masuyo Miyake; Hiromichi Oshiro; Michael Bouvet; Michiaki Unno; Robert M Hoffman
Journal:  Cell Cycle       Date:  2018-05-21       Impact factor: 4.534

6.  Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics.

Authors:  Mike Mattie; Ashley Christensen; Mi Sook Chang; William Yeh; Suzanne Said; Yuriy Shostak; Linnette Capo; Alla Verlinsky; Zili An; Ingrid Joseph; Yi Zhang; Sathish Kumar-Ganesan; Karen Morrison; David Stover; Pia Challita-Eid
Journal:  Neoplasia       Date:  2013-10       Impact factor: 5.715

7.  Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention.

Authors:  Kei Kawaguchi; Qinghong Han; Shukuan Li; Yuying Tan; Kentaro Igarashi; Tasuku Kiyuna; Kentaro Miyake; Masuyo Miyake; Bartosz Chmielowski; Scott D Nelson; Tara A Russell; Sarah M Dry; Yunfeng Li; Arun S Singh; Mark A Eckardt; Michiaki Unno; Fritz C Eilber; Robert M Hoffman
Journal:  Cell Cycle       Date:  2018-03-19       Impact factor: 4.534

8.  Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer.

Authors:  Leo Christopher DeRosier; Donald J Buchsbaum; Patsy G Oliver; Zhi-Qiang Huang; Jeffrey C Sellers; William E Grizzle; Wenquan Wang; Tong Zhou; Kurt R Zinn; Joshua W Long; Selwyn M Vickers
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

9.  Mouse orthotopic lung cancer model induced by PC14PE6.

Authors:  Zheng Yun Cui; Jin Seok Ahn; Jee Yun Lee; Won Seog Kim; Ho Yeong Lim; Hyun Jung Jeon; Soo Won Suh; Jin Hoon Kim; Won Ho Kong; Ji Min Kang; Do Hyun Nam; Keunchil Park
Journal:  Cancer Res Treat       Date:  2006-12-31       Impact factor: 4.679

Review 10.  Identifying novel therapeutic agents using xenograft models of pediatric cancer.

Authors:  Raushan T Kurmasheva; Peter J Houghton
Journal:  Cancer Chemother Pharmacol       Date:  2016-05-18       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.